mCRC
Oncology · 2005–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fruquintinib Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for… | Sep 2024 | Recommended with restriction | input received Bowel Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| cetuximab Treatment of metastatic colorectal cancer (mCRC) — both first-line and second-line — in patients with RAS wild-type disease, with an alternative dosing regimen… | Mar 2024 | Recommended | input received Medical Oncology Group |
| regorafenib Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered suitable candidates for, available… | Nov 2021 | Not recommended | input received Bowel Cancer Australia |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Jul 2018 | Not recommended | 1 individuals |
| trifluridine/tipiracil Treatment of patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies… | Mar 2017 | Recommended with restriction | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Nov 2017 | Not recommended | input received Bowel Cancer Australia · Medical Oncology Group |
| panitumumab First-line and later-line treatment of metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumours. The submission requests amendment of the… | Jul 2014 | Recommended with restriction | none received |
| cetuximab First-line treatment in combination with chemotherapy (FOLFIRI) for patients with metastatic colorectal cancer (mCRC) whose tumours have RAS wild-type status. | Nov 2014 | Recommended with restriction | 2 individuals Bowel Cancer Australia |
| aflibercept Treatment of metastatic colorectal cancer previously treated with an oxaliplatin-based chemotherapy regimen, in combination with… | Jul 2013 | Not recommended | no section in document |
| cetuximab Treatment of metastatic colorectal cancer (MCRC) in patients who have failed standard chemotherapeutic options, specifically those with EGFR-expressing disease… | Nov 2005 | Not recommended | no section in document |
Who spoke
Bowel Cancer Australia · Medical Oncology Group · Rare Cancers Australia
What the PBS pays
$571M in government benefit over 2024–25, across 541,136 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| aflibercept | $506.1M |
| cetuximab | $42.5M |
| panitumumab | $12.8M |
| trifluridine with tipiracil | $9.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| panitumumabPanitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | terminated | 2011-12 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.